Pharvaris (NasdaqGS:PHVS) FY Conference Transcript

Summary of Pharvaris FY Conference Call Company Overview - Company: Pharvaris (NasdaqGS:PHVS) - Focus: Treatment of Hereditary Angioedema (HAE), a rare genetic condition characterized by painful and potentially fatal swelling attacks [4][5] Core Points and Arguments Company Background - Pharvaris was established 10 years ago, with a focus on addressing unmet needs in HAE treatment, particularly for an oral therapy option [4][6] - The company aims to develop deucrictibant, an oral B2 receptor antagonist, to provide a highly efficacious treatment for HAE and other forms of angioedema [7][8] Market Dynamics - The current market for HAE treatments is dominated by injectables, with approximately 63% of patients on long-term prophylaxis, representing about 80% of the market value [12][13] - The clinical guidelines suggest that ideally, HAE patients should never suffer from attacks, highlighting the need for effective prophylactic treatments [13] Clinical Data - The Phase 3 trial for deucrictibant in the on-demand setting showed significant results, with a primary endpoint met and all 11 secondary endpoints achieving statistical significance [16] - Key findings include: - Onset of symptom relief at 1.28 hours compared to 12 hours for placebo [17] - End of progression of the attack at 17 minutes, providing comfort to patients [17] - Faster complete resolution compared to standard care and recently approved oral therapies [19] Competitive Landscape - The oral therapy market is becoming increasingly competitive, with KalVista's EKTERLY recently launched. However, deucrictibant is positioned to differentiate itself through faster onset and resolution of symptoms [21][22] - The Phase 2 data for deucrictibant in the prophylactic setting showed an 84.5% attack reduction, comparable to injectable therapies [41] Regulatory and Commercial Strategy - Pharvaris plans to file for NDA in the first half of 2026, with a potential launch about a year later [20] - The company is expanding its Phase 3 studies to include a broader patient demographic and geographic range, which may mitigate risks associated with trial outcomes [45] Financial Outlook - The company has sufficient cash runway into the first half of 2027, with plans to ramp up commercial operations and team expansion [56][57] Additional Important Information - Pharvaris will present at the QUAD A conference, showcasing Phase 3 data and other significant findings, including a 92.3% attack reduction from an open-label extension study [53] - The company is also involved in community engagement, sponsoring events like the HAEA Foundation's 5K run [54] This summary encapsulates the key points discussed during the Pharvaris FY conference call, highlighting the company's strategic focus, clinical advancements, market positioning, and financial outlook.